

Missouri Cancer Registry

November 1, 2023

Fellow Registrars,

We are quickly approaching the holiday season! We hope your season is filled with good health and happiness. We thank you for submitting your cases in a timely manner and helping us meet our NPCR goals. We are actively preparing for the annual Call for Data.



November is Lung cancer Awareness month. Lung cancer continues to be the leading cause of cancer death in the US. Please see the attached one-pager for Missouri stats.



Lung Onepager.pdf

DUE DATES

To be on track, large hospitals (>500 cases/yr.) typically would be expected to have abstracted April 2023 diagnosis cases by November 15, 2023. Smaller facilities (<300 cases /yr.) are expected to report the 2nd Quarter of 2023 by January 15, 2024.

EDUCATION

MCR Help-Line

Reach us at 1-800-392-2829 during regular office hours or leave a message; a member of our QA team will return your call within one business day.

FiccSC-New Course Available!

Earn 3 CE's

NAACCR Webinar – Lung 2023 part 1 presented October 2023

NAACCR Webinars:

NAACCR Webinar: Lung 2023 part 2

November 2, 2023, 8-11 a.m., Part 2 of the Lung webinar will focus on treatment of lung cancer. We will discuss the surgery, lymph node related data items, systemic treatment, and radiation.

To attend the live broadcast in Columbia, Mo, sign up here:

<https://www.signupgenius.com/go/30E0E4BA9A823A6FB6-45426324-naacccr>

Visitor Parking at Parking Structure 7 (PS7) for NAACCR Webinars

Only those with a valid PS7 visitor permission pass will be allowed to park there. A daily visitor permit is \$7 for parking in lots and \$9 for parking garages. Violators are subject to ticketing and towing.

You can purchase a visitor pass online at <https://missouri.nupark.com/v2/Portal/Login>

Fundamentals of Abstracting Workshop – Winter 2023

MCR is hosting an on-line Fundamentals of Abstracting course beginning December 1, 2023, to be taken at your own pace through January 15, 2024. This class is geared toward new abstractors who are not familiar with the abstracting process. If you are not familiar with abstracting and/or the required fields, this is a great place to start learning. Students will view fifteen pre-recorded Voice Thread presentations of the Missouri Cancer Registry Abstract Code Manual at their own pace. When completed with the Voice Thread presentations students can work through five practice cases using the Missouri Cancer Registry and Research Abstract Code Manual. The cost of the course is \$50 and will be available on the University of Missouri Canvas platform. You can register and pay for this course by using the following Marketplace link or QR code: https://secure.touchnet.net/C20067_ustores/web/store_main.jsp?STOREID=248&SINGLESTORE=true

Registration is due by November 30, 2023



SEER Educate – October 2023

Welcome to CTR Prep Students and SEER Workshop Participants

2023 More STORE for CTR Prep

The goal in SEER*Educate, should you incorrectly answer a multiple-choice question, is to explain the broad concept(s) that applies in the rationale. The explanations in the rationale will help your understanding of the material. **DO NOT FOCUS** on the scores in SEER*Educate but rather focus on your understanding of the rationales. It is not necessary to score even 60% or 70% in SEER*Educate to pass the closed book portion of the CTR Exam. Best wishes to this year's students.

SEER Workshop Cases

There are three sets of cases:

- LAMN/HAMN - EOD, Summary Stage, Grade, SSDI (5 cases, 2.5 Category A CEs)
- Brain - site, histo, behavior (15 cases, 2.5 Category A CEs)
- Other sites – site, histo, behavior (20 cases, 3.0 Category A CEs)

Please visit the SEER Educational Workshop page for more information on registering for the meeting. (Separate meeting registration is needed. The meeting itself is free.)

Help Desk will be CLOSED

Nov 10-12

Nov 23-26

Dec 23-25

Dec 30-Jan 1

Log in or sign up at **SEER*Educate** today by visiting <https://educate.fredhutch.org/> and Learn by Doing!

ABSTRACTING TIP

To avoid the overreporting of breast ductal carcinoma, use **Rule M11 when a ductal carcinoma occurs less than five years after a combination code in the same breast.**

See the following from the Solid Tumor Rules-Breast Rule M11:

Abstract a **single primary** when a **ductal** carcinoma occurs **after a combination code** in the same breast.

- DCIS following a diagnosis of:
 - o DCIS + lobular carcinoma in situ 8522/2 OR
 - o DCIS + in situ Paget 8543/2 OR
 - o DCIS + Invasive Paget 8543/3 OR
 - o DCIS mixed with other in situ 8523/2 (code used for cases diagnosed prior to 1/1/2018)
- Invasive carcinoma NST/duct following a diagnosis of:
 - o Invasive duct + invasive lobular 8522/3 OR
 - o Invasive duct + invasive Paget 8541/3 OR
 - o Invasive duct + other invasive carcinoma 8523/3

DEATH CLEARANCE

The annual Death Clearance activities for reporting year 2021 are wrapping up. Thank you to all that have responded and provided essential information. This contribution helps MCR to continue to be successful in meeting our annual goals.

MCR NEWS

V23 Cases - MCR is accepting **2023** cases! The **V24** metafile and data dictionary have been posted to the NAACCR Clearinghouse.

NEWS FROM THE STANDARD SETTERS

2024 ICD-O Update and Guidelines

The 2024 Guidelines for ICD-O-3 Histology Code and Behavior Update for cases diagnosed 1/1/2024 forward have been released and are now available on the NAACCR website. The update includes tables listing new codes, terminology, and behavior changes and is available in .pdf format. The update also includes the annotated ICD-O-3.2. Excel document. The 2024 documents are available at: <https://www.naacr.org/icdo3/>

SEER - Cancer PathCHART

The Cancer Pathology Coding Histology and Registration Terminology (Cancer PathCHART) initiative has released the 2024 Cancer PathCHART ICD-O-3 Site Morphology Validation List (CPC SMVL). These tumor site-morphology combination standards for cancer surveillance in North America can be freely downloaded today by cancer registration software vendors and other end users at <https://seer.cancer.gov/cancerpathchart/products.html>. The four easily consumed, computer-readable file formats are CSV, XLSX, XML, and JSON. The 2024 CPC SMVL replaces both the ICD-O-3 SEER Site/Histology Validation List and the list of impossible site and histology combinations included in the Primary Site, Morphology-Impossible ICDO3 (SEER IF38) edit.

REGISTRY TO RESEARCH

2008 to 2020 Saw Increase in Survival for Advanced Prostate Cancer
<https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2809974>

Survival Varies by Race, Ethnicity for Nonmetastatic Castration-Resistant Prostate Cancer (VA Health Administration)
<https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2810483>

Incidence of Lung Cancer Higher in Women Versus Men Aged 35 to 54 Years (ACS)

<https://jamanetwork.com/journals/jamaoncology/article-abstract/2810384>

RESOURCES AND ITEMS OF INTEREST

FDA Approves Nivolumab as Adjuvant Treatment for Melanoma <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-adjuvant-treatment-stage-ii-bc-melanoma>

Selenium Not Linked to Recurrence of Non-Muscle-Invasive Bladder Cancer

<https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2810773>

Bariatric Surgery Linked to Reduced Incidence of Hematologic Cancer

[https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568\(23\)00141-1/fulltext](https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(23)00141-1/fulltext)

Prevalence of Hearing Loss Significantly Higher for Cancer Survivors

<https://jamanetwork.com/journals/jamaotolaryngology/article-abstract/2810145>

Warm regards,

Lucinda Ham, RHIA, CTR

QA Manager, Missouri Cancer Registry

Department of Public Health

1095 Hospital Drive | Columbia MO 65211

O: 573-882-7775 | **C:** 573-220-2438

F: 573-884-9655 | **E:** lahf5p@health.missouri.edu

W: <https://umurl.us/missouri-cancer-registry>

“The only impossible journey is the one you never begin” – Tony Robbins

 **College of Health Sciences**
University of Missouri

Missouri Cancer Registry and Research Center is supported in part by a cooperative agreement between the Centers for Disease Control and Prevention (CDC) and the Missouri Department of Health and Senior Services (DHSS) (DP2202-22-02) and a Surveillance Contract between DHSS and the University of Missouri.

